Researchers discovered that intervertebral discs age remarkably slowly due to a unique cellular mechanism: they degrade hypoxia-inducible factor-1α (HIF-1α) through optineurin-mediated selective autophagy, preventing the typical cellular stress response to low oxygen. This finding led to development of HATC, a small-molecule compound that exports this protective mechanism systemically. Weekly HATC administration in aged mice reduced HIF-1α levels across multiple organs and extended median lifespan by 14% and maximum lifespan by 12%. This represents a significant breakthrough in longevity research, as few interventions achieve double-digit lifespan extension in mammals. The discovery challenges conventional wisdom that hypoxia universally drives aging through HIF-1α accumulation. Instead, it reveals that controlled HIF-1α degradation under hypoxic conditions can be profoundly protective. The translational potential is substantial—HATC could theoretically be developed for human use, though the mouse study limitations include single-species testing and unknown long-term effects. This work establishes a novel geroprotective pathway and provides a concrete therapeutic target for healthspan extension.